Stockholm, 15 January 2010

XCounter notification of changes in significant shareholdings
XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of
photon counting X-ray detectors and tomosynthesis based 3D medical imaging,
announces today that it has received notification from XR Invest AS that it has
purchased 11,818,181 XCounter shares representing 13.05 % of the issued share
capital of XCounter.


Stockholm, 03 December 2009



XCounter notification of changes in significant shareholdings


XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of
photon counting X-ray detectors and tomosynthesis based 3D medical
imaging, announces it has received notification from Whitehorse Investing Ltd
("Whitehorse") that it has purchased 4,100,000
XCounter shares representing
9.41 % of the issued share capital of XCounter, from HealthCap. The Company has
also received notification that funds managed by HealthCap RNS Number : 5924E
XCounter AB
22 December 2009

PRESS RELEASE




Stockholm, 22 December 2009



XCounter notification of changes in significant shareholdings


XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of
photon counting X-ray detectors and tomosynthesis based 3D medical imaging,
announces today that it has received notification from Whitehorse Investing Ltd
("Whitehorse") that on the 21st December 2009 it purchased 734,786 XCounter
shares taking its total shareholding to 4,834,786 shares which represents 11.1 %
of XCounter.

NEW YORK, Dec. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:


Radiation Therapy Equipment - A Global Market Review

http://www.reportlinker.com/p0164337/Radiation-Therapy-Equipment---A-Global-Market-Review.html


Cancer is a growing concern worldwide with millions of new cancer cases diagnosed each year. Radiation therapy is the leading non-surgical technique, utilized in the treatment of cancer patients. An aging population, increasing life expectancies, and rising incidence of cancer continue to enhance demand for radiation therapy, globally. Further, technological advancements are driving the development of sophisticated screening methods that facilitate early cancer detection.


These and other market data and trends are presented in "Radiation Therapy Equipment: A Global Market Review" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
XCounter AB (publ) (AIM: XCT), a technology leader in the development and
commercialisation of 3D medical imaging, has announced a commercial partnership
with the global leader in brachytherapy, Nucletron B.V.


In this first step of the cooperation between Nucletron and XCounter, the latter will evaluate
the properties of a novel imaging system for brachytherapy treatments. This evaluation is a
pre-study prior to moving to a full agreement on the development of a dedicated imaging
system for brachytherapy, especially designed for Nucletron.


The incidence of most cancer types is growing. Approximately 50% of all men and 30% of
all women in the USA will develop some kind of cancer at some point in their lives (NIH,
2002). This means that the need for effective methods for cancer treatment, such as
brachytherapy, is growing rapidly.


High image quality and low dose imaging are vital components in precision cancer
treatment. We find XCounters imaging principles very attractive and are looking forward to
the results of this pre-study, says Dick van Waes, Business Director Brachytherapy and
Imaging of Nucletron.


It is with great pleasure that we can announce XCounters commercial partnership with
Nucletron. Nucletron has chosen to cooperate with XCounter as a result of our unique
imaging concepts, as well as our ability to handle development on behalf our customers. In
line with our business concept, which is to invent and develop innovative patient and disease
specific imaging systems and concepts for leading medical companies, the agreement is a
further recognition of the capabilities of our company as we continue partnering discussions
for the XC Mammo -3T, says Tom Francke, CEO at XCounter. We are looking forward to a
fruitful cooperation with Nucletron.


Brachytherapy is a high precision, minimally invasive radiation therapy, favourably used for
cancer treatment in parts of the body which have sensitive adjacent organs. Examples of such
treatment areas are gynaecological body sites, breast, bladder, brain, head and neck, lung,
esophagus and prostate

XCOUNTER AB/XCT anytime soon wait for the A.A BUY.Co-development of the breast CT scanner provides a cost effective way for XCounter to progress the
development of the detector technology as, under the current proposals, Artemis intends to provide 1.75m
over a period of two years during the R&D phase of the project. Artemis would fund XCounter's detector
development in return for exclusivity for the PCT technology in the Mammo CT application.
Artemis has applied for a 2.8m grant from the German government (Bundesministerium f Bildung und
Forschung) to fund half of the project. It is currently anticipated that the German government will announce
the results of the grant application on or around 26 January 2010.
If Artemis' application for the grant is successful, the Company anticipates negotiating and signing a co-
development agreement with Artemis in the first quarter of 2010 which will include provisions granting
Artemis exclusivity for the PCT technology for the Mammo CT application. Following the developmental
phase, Artemis proposes to licence the product to a major OEM and it is XCounter's current intention at that
time to enter into a supply agreement with Artemis, so as to exclusively manufacture and supply the detector
components to be integrated into the completed Mammo CT device.
The Directors believe that the total initial market for the complete Mammo
CT systems to be 150m per annum